Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.
KTRADelisted Stock | USD 6.30 0.14 2.17% |
About 62% of Kintara Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Kintara Therapeutics suggests that many traders are alarmed regarding Kintara Therapeutics' prospects. The current market sentiment, together with Kintara Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Kintara Therapeutics stock news signals to limit their universe of possible portfolio assets.
Kintara |
Kintara Therapeutics, Inc. a biopharmaceutical company focused on the development of new solid tumor cancer therapies, encourages all stockholders to vote at the upcoming Special Meeting of Stockholders to allow for completion of the proposed merger with TuHURA Biosciences, Inc. . As previously announced, Kintara entered into a definitive agreement for an all-stock transaction with TuHURA to form
Read at finance.yahoo.com
Kintara Therapeutics Fundamental Analysis
We analyze Kintara Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kintara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kintara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Kintara Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Kintara Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kintara Therapeutics stock to make a market-neutral strategy. Peer analysis of Kintara Therapeutics could also be used in its relative valuation, which is a method of valuing Kintara Therapeutics by comparing valuation metrics with similar companies.
Peers
Kintara Therapeutics Related Equities
ONCY | Oncolytics Biotech | 2.47 | ||||
MCRB | Seres Therapeutics | 1.14 | ||||
SCPH | Scpharmaceuticals | 0.31 | ||||
LUMO | Lumos Pharma | 0.23 | ||||
MIST | Milestone Pharmaceuticals | 0.56 | ||||
TOVX | Theriva Biologics | 0.85 | ||||
VCNX | Vaccinex | 1.08 | ||||
DMAC | DiaMedica Therapeutics | 1.30 | ||||
BOLT | Bolt Biotherapeutics | 1.89 | ||||
GOVX | GeoVax Labs | 2.55 | ||||
SABS | SAB Biotherapeutics | 2.94 | ||||
SLRX | Salarius Pharmaceuticals | 5.44 | ||||
LSTA | Lisata Therapeutics | 5.49 | ||||
DYAI | Dyadic International | 8.59 | ||||
CLRB | Cellectar Biosciences | 16.13 | ||||
FBRX | Forte Biosciences | 18.10 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |